A new review was published in Volume 16 of Oncotarget on June 25, 2025, titled "Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights ...

Lung cancer in never-smokers exhibits distinct biological characteristics, often leading to late-stage diagnoses due to lack of screening. Targeted therapies, guided by molecular testing, offer ...

In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically ...

An expert discusses how long-term safety considerations are evaluated through clinical trial data and postmarketing surveillance, emphasizing the importance of reporting unexpected adverse events to ...

A newly discovered gene switch may help turn chemotherapy-resistant pancreatic cancer into a treatable disease.

Each year, approximately 36,000 people are diagnosed with the disease in the United States, according to the American Cancer ...

HER2-positive breast cancer is driven by HER2 protein overexpression, historically linked to poor outcomes but now improved by targeted therapies. Treatment varies by stage, involving surgery, ...

Identifying BRCAness in tumors, even in the absence of BRCA mutations, broadens the reach of targeted therapies, supporting more individualized and effective cancer treatment approaches. BRCAness ...

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

Scientists at Duke-NUS Medical School have identified a molecular "switch" that determines whether pancreatic cancer cells resist chemotherapy or respond to it—a finding that could help convert some ...

The biliary tract cancer epidemiology section provides insights into the historical and current biliary tract cancer patient pool and forecasted trends for the leading markets. In 2024, the majority ...

The past 30 years have seen tremendous progress in our fundamental understanding of lung cancer and the development of new treatment strategies,” senior researcher Dr. Cary Gross, a professor at Yale ...